Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review

耐碳青霉烯类肠杆菌科 肠杆菌科 碳青霉烯 美罗培南 医学 抗药性 亚胺培南 肺炎克雷伯菌 抗生素耐药性 感染控制 抗菌剂 微生物学 重症监护医学 生物 抗生素 大肠杆菌 基因 生物化学
作者
Mihret Tilahun,Yeshimebet Kassa,Alemu Gedefie,Melaku Ashagrie Belete
出处
期刊:Infection and Drug Resistance [Dove Medical Press]
卷期号:Volume 14: 4363-4374 被引量:170
标识
DOI:10.2147/idr.s337611
摘要

Infections due to multidrug-resistant Enterobacteriaceae have become major international public health problem due to the inadequate treatment options and the historically lagged pace of development of novel antimicrobial drugs. Inappropriate antimicrobial use in humans and animals coupled with increased global connectivity aided to the transmission of drug-resistant Enterobacteriaceae infections. Carbapenems are the medications of choice for extended-spectrum beta-lactamase and AmpC producers, but alternatives are currently needed because carbapenem resistance is increasing globally. This review pointed to discuss emerging drug-resistant Enterobacteriaceae, its epidemiology and novel treatment options for infections, which date back from 2010 to 2019 by searching Google Scholar, PubMed, PMC, Hinari and other different websites. The occurrence of carbapenem-resistant Enterobacteriaceae is reported worldwide with great regional variability. The rise of carbapenem-resistant Enterobacteriaceae poses a threat to all nations. Enzyme synthesis, efflux pumps, and porin mutations are the main methods by which Enterobacteriaceae acquire resistance to carbapenems. The major resistance mechanism among these is enzyme synthesis. Most carbapenem resistance is caused by three enzyme groups: Klebsiella pneumoniae carbapenemase (Ambler class A), metallo-ß-lactamases (Ambler class B), and oxacillinase-48 (Ambler class D). Ceftazidime-avibactam, which was newly licensed for carbapenemase producers, is the most common treatment option for infections. Meropenem-vaborbactam, imipenem-relebactam, plazomicin, cefiderocol, eravacycline, and aztreonam-avibactam are recently reported to be active against carbapenem-resistant Enterobacteriaceae; and are also in ongoing trials for different populations and combinations with other antibacterial agents. Overall, treatment must be tailored to the patient's susceptibility profile, type and degree of infection, and personal characteristics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
marvelou完成签到,获得积分10
1秒前
2秒前
2秒前
Remua发布了新的文献求助10
2秒前
Fu发布了新的文献求助10
3秒前
4秒前
5秒前
qf完成签到,获得积分10
6秒前
7秒前
完美世界应助kiki采纳,获得10
7秒前
马邦德发布了新的文献求助10
7秒前
科研通AI6.2应助鳗鱼灵槐采纳,获得10
8秒前
8秒前
没救的猴子完成签到,获得积分10
8秒前
9秒前
口合口合完成签到 ,获得积分10
9秒前
安静风华发布了新的文献求助10
10秒前
屠建锋完成签到,获得积分10
10秒前
zeroyhyo发布了新的文献求助10
11秒前
科研通AI6.1应助Hushluo采纳,获得10
11秒前
12秒前
空古悠浪完成签到,获得积分10
12秒前
13秒前
HsuMing完成签到,获得积分10
16秒前
香蕉觅云应助在写了采纳,获得10
17秒前
温依澜发布了新的文献求助10
17秒前
小黄完成签到 ,获得积分10
18秒前
hiimsakura完成签到,获得积分10
19秒前
祁淑娴完成签到 ,获得积分10
20秒前
JamesPei应助现代的手套采纳,获得10
23秒前
23秒前
25秒前
科研通AI6.1应助zeroyhyo采纳,获得10
25秒前
26秒前
打打应助niko采纳,获得10
26秒前
所所应助liyixin采纳,获得10
26秒前
Fu完成签到,获得积分10
27秒前
angry_yu完成签到,获得积分10
27秒前
28秒前
高分求助中
Clinical Epidemiology: The Essentials, 6e 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Graphene Handbook (2019 Edition) 800
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6543699
求助须知:如何正确求助?哪些是违规求助? 8333400
关于积分的说明 17857722
捐赠科研通 5651355
什么是DOI,文献DOI怎么找? 2937063
邀请新用户注册赠送积分活动 1913326
关于科研通互助平台的介绍 1775573